Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

378 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer.
Conte P, Schneeweiss A, Loibl S, Mamounas EP, von Minckwitz G, Mano MS, Untch M, Huang CS, Wolmark N, Rastogi P, D'Hondt V, Redondo A, Stamatovic L, Bonnefoi H, Castro-Salguero H, Fischer HH, Wahl T, Song C, Boulet T, Trask P, Geyer CE Jr. Conte P, et al. Among authors: redondo a. Cancer. 2020 Jul 1;126(13):3132-3139. doi: 10.1002/cncr.32873. Epub 2020 Apr 14. Cancer. 2020. PMID: 32286687 Free PMC article. Clinical Trial.
An 8-gene qRT-PCR-based gene expression score that has prognostic value in early breast cancer.
Sánchez-Navarro I, Gámez-Pozo A, Pinto A, Hardisson D, Madero R, López R, San José B, Zamora P, Redondo A, Feliu J, Cejas P, González Barón M, Angel Fresno Vara J, Espinosa E. Sánchez-Navarro I, et al. Among authors: redondo a. BMC Cancer. 2010 Jun 28;10:336. doi: 10.1186/1471-2407-10-336. BMC Cancer. 2010. PMID: 20584321 Free PMC article.
Gene profiling in breast cancer: time to move forward.
Espinosa E, Vara JÁ, Navarro IS, Gámez-Pozo A, Pinto A, Zamora P, Redondo A, Feliu J. Espinosa E, et al. Among authors: redondo a. Cancer Treat Rev. 2011 Oct;37(6):416-21. doi: 10.1016/j.ctrv.2010.12.009. Epub 2011 Feb 1. Cancer Treat Rev. 2011. PMID: 21277684 Review.
A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM).
González A, Lluch A, Aba E, Albanell J, Antón A, Álvarez I, Ayala F, Barnadas A, Calvo L, Ciruelos E, Cortés J, de la Haba J, López-Vega JM, Martínez E, Muñoz M, Peláez I, Redondo A, Rodríguez Á, Rodríguez CA, Ruíz A, Llombart A. González A, et al. Among authors: redondo a. Clin Transl Oncol. 2017 May;19(5):616-624. doi: 10.1007/s12094-016-1571-4. Epub 2016 Nov 16. Clin Transl Oncol. 2017. PMID: 27853985 Review.
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. von Minckwitz G, et al. Among authors: redondo a. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5. N Engl J Med. 2019. PMID: 30516102 Clinical Trial.
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, du Toit Y, Easton V, Lindegger N, Miles D; PERUSE investigators. Bachelot T, et al. Ann Oncol. 2019 May 1;30(5):766-773. doi: 10.1093/annonc/mdz061. Ann Oncol. 2019. PMID: 30796821 Free article. Clinical Trial.
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer.
Lorusso D, Hilpert F, González Martin A, Rau J, Ottevanger P, Greimel E, Lück HJ, Selle F, Colombo N, Kroep JR, Mirza MR, Berger R, Pardo B, Grischke EM, Berton-Rigaud D, Martinez-Garcia J, Vergote I, Redondo A, Cardona A, Bastière-Truchot L, du Bois A, Kurzeder C; PENELOPE trial investigators. Lorusso D, et al. Among authors: redondo a. Int J Gynecol Cancer. 2019 Sep;29(7):1141-1147. doi: 10.1136/ijgc-2019-000370. Epub 2019 Aug 15. Int J Gynecol Cancer. 2019. PMID: 31420414 Clinical Trial.
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial.
Kurtz JE, Pujade-Lauraine E, Oaknin A, Belin L, Leitner K, Cibula D, Denys H, Rosengarten O, Rodrigues M, de Gregorio N, Martinez García J, Petru E, Kocián R, Vergote I, Pautier P, Schmalfeldt B, Gaba L, Polterauer S, Mouret Reynier MA, Sehouli J, Churruca C, Selle F, Joly F, D'Hondt V, Bultot-Boissier É, Lebreton C, Lotz JP, Largillier R, Heudel PE, Heitz F; ATALANTE/ENGOT-ov29 Investigators. Kurtz JE, et al. J Clin Oncol. 2023 Oct 20;41(30):4768-4778. doi: 10.1200/JCO.23.00529. Epub 2023 Aug 29. J Clin Oncol. 2023. PMID: 37643382 Free PMC article. Clinical Trial.
High-throughput techniques in breast cancer: a clinical perspective.
Espinosa E, Redondo A, Vara JA, Zamora P, Casado E, Cejas P, Barón MG. Espinosa E, et al. Among authors: redondo a. Eur J Cancer. 2006 Mar;42(5):598-607. doi: 10.1016/j.ejca.2005.11.021. Epub 2006 Jan 23. Eur J Cancer. 2006. PMID: 16431104 Review.
378 results